Similar to our findings, the concomitant KRAS mutation and amplification has a predictive effect for greater benefit from treatment in KRAS-mutated lung cancers,48 and high allele fraction for BRAF mutation, which is an adverse prognostic factor in colorectal cancers, is associated with a higher benefit from triplet therapy with EGFR-BRAF-MEK inhibitors (OS HR = 0.17) compared to the cancers with low BRAF mutation allele frequency cancers (OS HR = 0.90).49 Here, MAP2K7 is linked to lung cancer.